{"id":"ae37-peptide-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The AE37 Peptide vaccine is a type of cancer vaccine that works by presenting specific peptides from cancer cells to the immune system, allowing it to recognize and target these cells for destruction. This process is thought to induce a specific immune response against cancer cells, potentially leading to tumor shrinkage or slowing of disease progression.","oneSentence":"AE37 Peptide vaccine stimulates the immune system to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:08.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT04024800","phase":"PHASE2","title":"Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"NuGenerex Immuno-Oncology","startDate":"2019-05-03","conditions":"Triple-negative Breast Cancer","enrollment":29},{"nctId":"NCT00524277","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Breast Cancer","status":"COMPLETED","sponsor":"San Antonio Military Medical Center","startDate":"2007-01","conditions":"Breast Cancer","enrollment":456}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AE37"],"phase":"phase_2","status":"active","brandName":"AE37 Peptide vaccine","genericName":"AE37 Peptide vaccine","companyName":"NuGenerex Immuno-Oncology","companyId":"nugenerex-immuno-oncology","modality":"Biologic","firstApprovalDate":"","aiSummary":"AE37 Peptide vaccine stimulates the immune system to recognize and attack cancer cells. Used for Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}